Achilles Therapeutics plc (ACHL): Price and Financial Metrics


Achilles Therapeutics plc (ACHL): $2.50

0.05 (+2.04%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ACHL Stock Price Chart Interactive Chart >

Price chart for ACHL

ACHL Price/Volume Stats

Current price $2.50 52-week high $13.00
Prev. close $2.45 52-week low $1.84
Day low $2.50 Volume 111
Day high $2.50 Avg. volume 88,817
50-day MA $2.60 Dividend yield N/A
200-day MA $4.63 Market Cap 101.51M


ACHL Latest News Stream


Event/Time News Detail
Loading, please wait...

ACHL Latest Social Stream


Loading social stream, please wait...

View Full ACHL Social Stream

Latest ACHL News From Around the Web

Below are the latest news stories about Achilles Therapeutics plc that investors may wish to consider to help them evaluate ACHL as an investment opportunity.

Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.

Internationally recognized experts bring extensive scientific and clinical research expertise in cancer immunology and immunotherapyLONDON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of Alena Gros, Ph.D. and Ben Creelan, M.D. to its Scientific Advisory Board (SAB). “We are very pleased to welcome leading experts Dr. Gros and Dr.

Yahoo | February 7, 2022

Achilles Therapeutics Provides Business Update and Outlook for 2022

LONDON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announces a business update and reflects on recent progress with its pioneering, personalized T cell therapy programs targeting clonal neoantigens known as cNeT. As the original mutations formed early in cancer’s development, clonal neoantigens are protein markers that are present on all of an individual’

Yahoo | January 13, 2022

Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | December 28, 2021

Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference

LONDON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022, at 8:15 a.m. ET. A live and archived webcast of the presentation will be available in the Events & Presentations section of the Achilles website. About

Yahoo | December 21, 2021

Achilles Therapeutics Added to the NASDAQ Biotechnology Index

LONDON, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that the Company has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open today, Monday, December 20, 2021. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified

Yahoo | December 20, 2021

Read More 'ACHL' Stories Here

ACHL Price Returns

1-mo 2.88%
3-mo -24.92%
6-mo -48.35%
1-year -80.48%
3-year N/A
5-year N/A
YTD -50.10%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6151 seconds.